Loading
A phase 3 trial of Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib in mantle cell lymphoma, run by Loxo Oncology, Inc., active and no longer recruiting.
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) is a phase 3 interventional study registered as NCT04662255 by Loxo Oncology, Inc., with 500 participants enrolled, started 2021-04-08 and due to reach its primary completion in 2027-01. Interventions recorded: Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pirtobrutinib, Ibrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Acalabrutinib, Ibrutinib and the tag pipeline.
Shares Pirtobrutinib, Mantle cell lymphoma and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Zanubrutinib, Acalabrutinib and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/